Oncternal Therapeutics, Inc. (GTU.F)

0,0000 -6,5200 (-100,00%) Ab 09:00AM CEST. Markt geöffnet.

Oncternal Therapeutics, Inc.

12230 El Camino Real
Suite 230
San Diego, CA 92130
United States
858 434 1113
https://www.oncternal.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 27

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. James B. Breitmeyer M.D., Ph.D.	President, CEO & Director	761,18k	N/A	1954
Dr. Salim Yazji M.D.	Chief Medical Officer	513,14k	N/A	1969
Mr. Richard G. Vincent CPA	CFO & Treasurer	490,04k	N/A	1964
Dr. Rajesh Krishnan Ph.D.	Chief Technical & Scientific Officer	N/A	N/A	1974
Mr. Chase C. Leavitt	General Counsel & Secretary	N/A	N/A	1982
Mr. Pablo Urbaneja	Senior Vice President of Corporate Development	N/A	N/A	N/A
Anita Wiseth	Senior Vice President of Human Resources	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.

Corporate Governance

Oncternal Therapeutics, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.